Dedifferentiated Liposarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Dedifferentiated liposarcoma, the rarest form of liposarcoma, typically arises from a well-differentiated liposarcoma (WDLPS). Its progression occurs in 17% of patients when WDLPS is located in the retroperitoneum and 6% when it occurs in the extremities. This condition is characterized as an atypical liposarcoma that changes over time, exhibiting varying histologic grades. It combines the features of a low-grade liposarcoma with those of a high-grade spindle cell sarcoma. This tumor predominantly affects adults beyond their 60s, with a slight male predominance, and is most commonly found in the abdominal cavity. The most frequently observed phenotype resembles pleomorphic malignant fibrous histiocytoma, although other sarcomatous phenotypes have been described less frequently. Surgical intervention is the primary treatment for dedifferentiated liposarcoma.

·       However, it is associated with a reported local recurrence rate of 41% to 52%, a distant metastatic rate of 15%, and a disease-related mortality rate of 30%.

 

Thelansis’s “Dedifferentiated Liposarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dedifferentiated Liposarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Dedifferentiated Liposarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Dedifferentiated Liposarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Dedifferentiated Liposarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Dedifferentiated Liposarcoma, Dedifferentiated Liposarcoma market outlook, Dedifferentiated Liposarcoma competitive landscape, Dedifferentiated Liposarcoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)